Poster
BLU-701 tumour suppression and intracranial activity as a single agent and in combination with BLU-945 in models of non-small cell lung cancer driven by EGFR mutations
Condition
non-small cell lung cancer
Drug target
EGFR
Source url
s3://convoke-optic-posters/2024-05-10/Blueprint-Medicines-BTOG-2022-BLU-701-BLU-945-EGFRm-NSCLC-Preclinical-Poster.pdf
1 organization
1 product
Product
BLU-701, BLU-945Organization
Blueprint Medicines